News Sentiment

TARA sentiment intelligence

Protara Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.32 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+6.4% over one week, +10.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

What's Driving Protara's Recent Surge

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 6.4% Price confirming higher
Trend fit Trend inactive 10.8% over four weeks
Fair value 20.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 47
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
TradingView 8
Market source 6
simplywall.st 5
GlobeNewswire 4
MT Newswires 2
TradingKey 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 18
Analyst action 3
Deals and strategy 2
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

Millennium Group and Israel Englander report 5.7% stake in Protara (TARA)

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 5.7% stake in Protara Therapeutics (TARA), while Integrated Core Strategies (US) LLC reported a 5.1% stake. These entities collectively hold shared voting and dispositive power ove

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 22:41
Source
Stock Titan
AD HOC NEWS Direct company coverage

Protara Therapeutics focuses on rare disease programs as development continues

Protara Therapeutics, a clinical-stage biopharmaceutical company, is advancing its rare and specialty disease pipeline. The company's stock value is heavily influenced by scientific milestones, strategic decisions, and capital market conditions, as it relies on existing cash and

Tone
Positive 64/100
Event
Balance sheet
Published
07 Jul 2026 13:12
Source
AD HOC NEWS
TradingView Direct company coverage

Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – NASDAQ:TARA

This article provides the enterprise value to EBITDA forward for Protara Therapeutics, Inc. (NASDAQ: TARA). It's presented within a financial data context on a trading platform, indicating the company's valuation metric for investors. The content itself is minimalist, primarily s

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 16:39
Source
TradingView
TradingView Direct company coverage

Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA)

This article provides an overview of Protara Therapeutics, Inc. (HAM:1KPA) stock, including its financial actuals and estimates, price forecasts from analysts, and historical price performance. It details the company's past earnings, revenue, net income, and confirms that it does

Tone
Positive 65/100
Event
Earnings
Published
05 Jul 2026 10:39
Source
TradingView
TipRanks Direct company coverage

Protara Therapeutics Announces Key Medical Leadership Transition

Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, who is leaving to pursue other opportunities. His responsibilities will be transferred to Lead Medical Director Carla Beckham, under the continued oversight of Chief Research & De

Tone
Negative 36/100
Event
Market update
Published
02 Jul 2026 21:48
Source
TipRanks
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)

This article examines analyst ratings for three healthcare companies: Sarepta Therapeutics (SRPT), Illumina (ILMN), and Protara Therapeutics (TARA). Sarepta Therapeutics has a Hold rating from Morgan Stanley with a $25.00 price target, and RBC Capital also maintains a Hold rating

Tone
Positive 70/100
Event
Analyst action
Published
02 Jul 2026 11:41
Source
The Globe and Mail
Stock Titan Direct company coverage

Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts

Protara Therapeutics CEO Jesse Shefferman exercised stock options to acquire 215,687 shares at $1.91 each and subsequently sold all of them for a weighted average price of $4.09 per share. He also made bona fide gift transfers of 30,000 shares. Following these transactions, Sheff

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – GETTEX:1KPA

This article provides financial information for Protara Therapeutics, Inc. (1KPA) on Gettex, specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is currently closed with no trades. The article is a financial data page from

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 10:40
Source
TradingView
Investing.com South Africa Direct company coverage

Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com

This article announces the filing of Form 144 for Protara Therapeutics (TARA) on June 29. Form 144 indicates an intent to sell restricted securities, which can sometimes impact a stock's short-term performance. The article provides only this brief, factual announcement from Inves

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 06:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

[144] Protara Therapeutics, Inc. SEC Filing

Protara Therapeutics, Inc. (TARA) has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 215,687 common shares by Morgan Stanley Smith Barney LLC, acquired through a stock option exercise on June 29, 2026, with an aggregate mar

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned

Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026. His responsibilities will be absorbed by Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, under the supervision of Jacqu

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 21:10
Source
Stock Titan
Finviz Direct company coverage

TARA - Protara Therapeutics Inc Options

This article provides detailed financial data and performance metrics for Protara Therapeutics Inc. (TARA), including its stock price, market capitalization, income, sales, key financial ratios, and insider/institutional ownership. It also lists EPS growth rates, analyst recommen

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 20:09
Source
Finviz
TradingView Direct company coverage

Protara Therapeutics, Inc. Actuals & Estimates (MUN:1KPA)

This article provides an overview of Protara Therapeutics, Inc. (MUN:1KPA) financial data and analyst estimates, including actual results versus estimates, stock forecasts, and historical price movements. It also details the company's latest earnings, revenue, net income, and upc

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Protara Therapeutics, Inc. Actuals & Estimates (FWB:1KPA)

This article provides an overview of Protara Therapeutics, Inc. (FWB:1KPA) including its stock performance, financial estimates, and actual results. It details analyst forecasts for the stock price, historical highs and lows, and information regarding its earnings, revenue, and e

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Protara Therapeutics, Inc. – FWB:1KPA

This article provides financial information for Protara Therapeutics, Inc. (FWB:1KPA) on TradingView, specifically focusing on its enterprise value to revenue forward. The content indicates that the market is currently closed with no trades recorded for the company on the Frankfu

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Protara Therapeutics, Inc. – NASDAQ:TARA

The article provides an overview of Protara Therapeutics, Inc. (NASDAQ:TARA)'s enterprise value to revenue forward. It notes that the market for TARA is closed with no recent trades. The content primarily consists of navigation links and various product/community/company informat

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Protara Therapeutics, Inc. – NASDAQ:TARA

This article provides a financial snapshot for Protara Therapeutics, Inc. (NASDAQ: TARA), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering various market data and analysis tools for investors and traders. The cont

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:09
Source
TradingView
TradingKey Direct company coverage

Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Protara Therapeutics Inc (TARA). It notes that relevant data for business segments and regional profit contributions have not yet been disclosed by the company for FY2019. The article highlights that the United States

Tone
Negative 42/100
Event
Earnings
Published
18 Jun 2026 13:10
Source
TradingKey
TradingKey Direct company coverage

Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Protara Therapeutics Inc (TARA) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and there is no data available for past stock splits. The current stock p

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 12:10
Source
TradingKey
Stock Titan Direct company coverage

Cynthia Smith granted 31,000 stock options at Protara Therapeutics (TARA)

Protara Therapeutics director Cynthia Smith was granted 31,000 stock options as equity compensation, with an exercise price of $3.94 per share. These options are set to vest fully on the first anniversary of the grant date, provided she continues her board service, and will also

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike

Protara Therapeutics director Michael Edward Solomon was granted 31,000 stock options with an exercise price of $3.94 per share. This grant, which vests fully on the first anniversary of the grant date or upon a Change of Control, allows him to purchase common stock and expires o

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94

Protara Therapeutics director Gregory Sargen was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, provided Sargen

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Protara (TARA) director granted 31,000 stock options at $3.94 strike

Protara Therapeutics director Richard S. Levy was granted 31,000 stock options with an exercise price of $3.94 per share. These options are set to fully vest on the first anniversary of the grant date, provided he remains on the board, or immediately upon a Change of Control. Thi

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94

Protara Therapeutics director Barry P. Flannelly was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date, provided the director continues to serve

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Protara (TARA) director receives 31,000 stock options at $3.94 strike

Protara Therapeutics director Luke M. Beshar was granted 31,000 stock options with an exercise price of $3.94 per share. These options were issued as an Annual Grant and will vest fully on the first anniversary of the grant date, provided he continues his service on the board, or

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:10
Source
Stock Titan